Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
暂无分享,去创建一个
C. Mamot | John W. Park | D. Drummond | C. Noble | D. Kirpotin | K. Hong | Daryl C Drummond | Keelung Hong | John W Park | Dmitri B Kirpotin | Christoph Mamot | Charles O Noble | V. Kallab | Zexiong Guo | Verena Kallab | Zexiong Guo
[1] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[2] F. Szoka,et al. Comparative properties and methods of preparation of lipid vesicles (liposomes). , 1980, Annual review of biophysics and bioengineering.
[3] Y. Barenholz,et al. Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.
[4] J. Drevs,et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study , 2004, Cancer Chemotherapy and Pharmacology.
[5] P. O'Brien. Procedures for comparing samples with multiple endpoints. , 1984, Biometrics.
[6] John W. Park,et al. Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.
[7] Lee M Ellis,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[9] C. Benz,et al. Development of ligand-targeted liposomes for cancer therapy , 2004, Expert opinion on therapeutic targets.
[10] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[11] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[12] Jianwei Zhu,et al. Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification , 2008, Biotechnology progress.
[13] A. Gabizon,et al. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.
[14] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] R. Chadwick,et al. EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines , 2004, Breast Cancer Research and Treatment.
[16] T. Allen,et al. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.
[17] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[18] Careen K. Tang,et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.
[19] G. R. Bartlett. Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.
[20] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[21] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[22] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Black,et al. Blood brain barrier permeability to temozolomide , 2005 .
[24] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[25] J. Baselga. The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.
[26] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[27] Udo Greiser,et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.
[28] M. Shibuya,et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.
[29] John W. Park,et al. Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis , 2008, Biotechnology progress.
[30] K. Aldape,et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. , 2001, Cancer research.
[31] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Godwin,et al. Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.
[33] D. Hicklin,et al. Epidermal growth factor receptor blockade by antibody IMC‐C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice , 2000, Cancer.
[34] P. Humphrey,et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.
[35] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[36] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[38] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[39] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] C. Mamot,et al. Development of novel liposomal and receptor tyrosine kinase-targeted immunoliposomal vinorelbine formulations with improved drug retention , 2005 .